证券代码：002332 证券简称：仙琚制药 公告编号：2025-055 浙江仙琚制药股份有限公司 第八届监事会第十三次会议决议公告 一、以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于部分 募集资金投资项目延期的公告》。 经审核，监事会认为：公司本次对募投项目的延期调整未改变募投项目的实 质内容，不存在改变或变相改变募集资金用途和损害公司及股东利益的情形，不 会对公司的正常经营产生重大不利影响，符合中国证监会和深圳证券交易所关于 募集资金存放和使用的相关规定。因此，监事会同意本次募投项目延期事项。 备查文件： 第八届监事会第十三次会议决议 特此公告。 浙江仙琚制药股份有限公司 监事会 2025 年 11 月 28 日 1 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2025年11月27日，浙江仙琚制药股份有限公司（以下简称"公司"）第八届 监事会第十三次会议在公司会议室以现场方式召开，会议通知及会议资料已于 2025年11月16日以电子邮件方式送达全体监事。会议由公司监事会主席吴天飞先 生召集和主持，会议应到监事7人，实到监事7人，董事会秘 ...

证券代码：002332 证券简称：仙琚制药 公告编号：2025-049 浙江仙琚制药股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）第八届董事会第十八次会议 于2025年11月27日在公司会议室召开。会议通知已于2025年11月16日以电子邮件方 式送达各位董事。本次董事会应到董事9名，实到董事9名，公司监事和高级管理人 员列席了本次会议，会议的召开符合《公司法》和《公司章程》等有关规定。会议 由董事长张宇松先生召集并主持，与会董事以现场投票表决方式通过以下决议： 一、会议以9票同意，0票弃权，0票反对，审议通过了《关于修订<公司章程> 的议案》。 具体内容详见刊登于2025年11月28日巨潮资讯网（www.cninfo.com.cn）的《关 于修订<公司章程>及公司部分治理制度的公告》（公告编号：2025-050）、修订后 的《公司章程》。本议案尚需提交公司2025年第三次临时股东大会审议。 二、会议以9票同意，0票弃权，0票反对，审议通过了《关于调整组织架构的议 案 ...

证券日报网讯仙琚制药（002332）11月26日在互动平台回答投资者提问时表示，股价受市场风格、行业 状况、公司发展阶段、公司业绩等多种因素影响。公司深耕主业，稳健经营，并通过连续、稳定的分红 政策，切实回报每一位投资者。面对近年来行业变化，公司将持续推动创新，以扎实的业绩、稳健的回 报等多种方式，驱动公司价值呈现。 ...

Core Insights - The core viewpoint of the article is that the power dynamics in China's anti-hair loss market have shifted from traditional daily chemical brands to pharmaceutical companies, driven by a growing consumer base and evolving market demands [4][5]. Market Dynamics - The anti-hair loss market in China has seen a significant transformation, with over 300 million people affected by hair loss, particularly among the 26-35 age group, indicating a shift from a minor issue to a widespread concern [4]. - Pharmaceutical companies, particularly those with OTC pipelines and dermatological resources, have emerged as the primary players in the market, leading to a dual oligopoly dominated by Sanofi's Mandi and Zhendong Pharmaceutical's Dafeixin [4][8]. - The market for anti-hair loss products has reached 5.247 billion yuan in sales within the first ten months of 2025, reflecting a year-on-year growth of over 47% [10][13]. Brand Strategies - Pharmaceutical companies are creating a new narrative of "anti-hair loss = medicine + consumer," leveraging high margins and professional barriers while extending their product lines into daily care categories [5][19]. - Brands like Mandi and Dafeixin are combining pharmaceutical and cosmetic products, promoting them through "scientific anti-hair loss salons" to capture consumer interest [6][9]. Competitive Landscape - Traditional daily chemical brands are struggling, with companies like Bawang reporting a significant decline in profits despite a slight revenue increase, highlighting a structural challenge in the market [8]. - The consumer focus has shifted from "shampoo for hair loss" to "medical treatment and scalp management," indicating a demand for more scientifically-backed solutions [9][10]. Emerging Trends - The average price of anti-hair loss products has risen to over 113 yuan, suggesting consumers are willing to invest more in effective scalp care solutions [13]. - New brands such as EHD and Off&Relax are gaining traction, with EHD leading in sales at 371 million yuan, showcasing a trend towards professional and functional care [16][18]. Future Directions - To compete effectively, beauty brands must transition from traditional narratives to scientific and medical language, focusing on the mechanisms behind hair loss and scalp health [19][23]. - The integration of devices with hair care products is emerging as a trend, with brands like Kérastase introducing scalp care devices that enhance treatment efficacy [25][27]. Conclusion - The anti-hair loss market is evolving into a sector characterized by scientific, medical, and long-term management approaches, with pharmaceutical companies redefining the rules and traditional brands being compelled to adapt [19].

从融资净买入金额来看，有26只个股获融资净买入超亿元。其中，蓝色光标、寒武纪-U、华胜天成融 资净买入金额排名前三，分别获净买入5.3亿元、3.57亿元、3.41亿元。 Wind数据显示，A股11月18日共有3742只个股获融资资金买入，有354股买入金额超亿元。其中，宁德 时代、蓝色光标、阳光电源融资买入金额排名前三，分别获买入19.31亿元、18.23亿元、16.87亿元。 从融资买入额占当日总成交金额比重来看，有8只个股融资买入额占比超30%。其中西部创业、仙琚制 药、森鹰窗业融资买入额占成交额比重排名前三，分别为35.86%、34.32%、33.85%。 ...

Group 1: Fund Research on Advanced Manufacturing - The report constructs a pool of actively managed advanced manufacturing theme funds, categorizing them into balanced and focused single-track funds, including themes like robotics, military, automotive, new energy, smart driving, and batteries [1][6][9] - Recommended funds in the robotics theme include Yongying Advanced Manufacturing Smart Selection, Penghua Carbon Neutral, Ping An Advanced Manufacturing, and AVIC Trend Navigation [1][6][9] - Recommended funds in the military theme include Changxin National Defense Military Industry, Huaxia Military Security, Yongying High-end Equipment Smart Selection, and others [1][6][10] Group 2: Securities Industry Strategy for 2026 - The report indicates a positive economic outlook, suggesting that the capital market's upward trend remains intact, with the brokerage sector being relatively undervalued and showing high year-on-year growth [2][12][14] - Recommended brokerage firms include Guotai Junan, Haitong Securities, Huatai Securities, Guosen Securities, and GF Securities, with a focus on companies benefiting from an active equity market [2][12][14] - The report anticipates a 23.5% year-on-year increase in net profit for the industry in 2026, driven by sustained inflows of incremental capital [2][14] Group 3: Communication Industry Report - The report highlights the rise of Scale-up network architecture, driven by the demand for high bandwidth and low latency in communication components [16][17] - The Scale-up switch market is projected to grow rapidly, with an estimated market size of nearly $6 billion by 2025 and a CAGR of 26% from 2025 to 2030 [16][17] - Key beneficiaries of the Scale-up network demand include high-end switching chips, integrated delivery of communication hardware, and short-distance high-speed copper connections [18][19] Group 4: Macroeconomic Data Analysis - The report notes a slowdown in industrial and service sector growth, with industrial value-added growth at 4.9% year-on-year in October, down from 6.5% in September [21][22] - Fixed asset investment saw a year-on-year decline of 12.2% in October, with significant drops in real estate development investment [22][23] - The government is increasing investment stabilization policies to achieve a 5% growth target for the year, including new policy financial tools and special bond quotas [23] Group 5: Solid-State Battery Industry Insights - The solid-state battery industry is expected to accelerate due to key policy drives, with significant funding allocated for research and development [29][30] - Major players like CATL and Zhongxin Innovation plan to achieve mass production of solid-state batteries by 2027, with safety improvements over liquid batteries [30][31] - Equipment manufacturers are likely to benefit first from the solid-state battery industry's growth, as they provide essential technology for production [31]

Core Points - The Shanghai Composite Index is at 4008.92 points, above the annual line, with a change of 0.22% [1] - A total trading volume of A-shares reached 894.89 billion yuan today [1] - 39 A-shares have surpassed the annual line, with notable stocks including Hangxin Technology, Liwang Co., and Chuanfa Longmang, showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 4008.92 points, reflecting a 0.22% increase [1] - The total trading volume for A-shares today is 894.89 billion yuan [1] Stocks Surpassing Annual Line - 39 A-shares have crossed the annual line, with the highest deviation rates recorded for: - Hangxin Technology: 4.59% - Liwang Co.: 3.56% - Chuanfa Longmang: 3.27% [1] - Other stocks with smaller deviation rates include: - Jiuzhou Group - Dali Kaipu - Tiens Wind Power [1] Detailed Stock Data - Notable stocks and their performance: - Hangxin Technology: +4.52%, turnover rate 5.95%, latest price 17.34 yuan, deviation rate 4.59% [1] - Liwang Co.: +5.42%, turnover rate 5.46%, latest price 28.02 yuan, deviation rate 3.56% [1] - Chuanfa Longmang: +3.57%, turnover rate 3.12%, latest price 13.07 yuan, deviation rate 3.27% [1]

Core Insights - The eczema formulation market is projected to grow from 4.03 billion to 5.28 billion yuan from 2019 to 2024, with a compound annual growth rate (CAGR) of 5.5% [1][11] - The primary patient demographic for eczema is adults aged 18 to 60, accounting for 51.6% of cases, while children aged 2 to 12 represent 20.7% of the patient population [1][9] - The industry is characterized by a clear supply chain, with upstream raw materials, midstream production, and downstream sales channels including hospitals and online platforms [6][7] Market Overview - Eczema formulations are designed to prevent, alleviate, or treat eczema through mechanisms such as anti-inflammatory effects, itch relief, skin barrier repair, and immune regulation [1][5] - The market is influenced by increasing eczema incidence due to environmental degradation and rising stress levels, alongside heightened consumer awareness regarding skin health [1][11] Industry Structure - Major players in the eczema formulation industry include both foreign and domestic pharmaceutical companies, with foreign firms dominating the high-end market and domestic companies competing effectively in the mid to low-end segments [1] - Key companies in the industry include Heng Rui Medicine, Innovent Biologics, Connoa, and Xianju Pharmaceutical [1] Research and Analysis - The research team utilized various analytical models such as SCP, SWOT, PEST, and regression analysis to assess the market environment, industry policies, competitive landscape, and technological innovations within the eczema formulation sector [2][20] - A comprehensive report titled "2026-2032 China Eczema Formulation Industry Development Outlook and Investment Strategy Research Report" has been compiled to provide insights for enterprises, research institutions, and investment organizations [2][20]

Core Viewpoint - Xianju Pharmaceutical's stock has shown a mixed performance in recent trading, with a slight increase in price and notable changes in trading volume and shareholder structure [1][2]. Group 1: Stock Performance - On November 11, Xianju Pharmaceutical's stock rose by 2.06%, reaching 9.92 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 2.20%, resulting in a total market capitalization of 9.813 billion CNY [1]. - Year-to-date, the stock price has increased by 3.98%, with a 4.86% rise over the last five trading days, a 3.55% increase over the last 20 days, but a decline of 6.42% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xianju Pharmaceutical reported a revenue of 2.826 billion CNY, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million CNY, down 23.29% year-on-year [2]. - Cumulatively, the company has distributed 2.031 billion CNY in dividends since its A-share listing, with 989 million CNY distributed over the last three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, the number of shareholders for Xianju Pharmaceutical was 49,600, a decrease of 0.82% from the previous period, with an average of 19,854 circulating shares per shareholder, an increase of 0.83% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 8.126 million shares as a new shareholder, while the Southern CSI 1000 ETF is the eighth largest, holding 7.238 million shares, a decrease of 97,000 shares from the previous period [3]. Group 4: Business Overview - Xianju Pharmaceutical, established on June 26, 2000, and listed on January 12, 2010, specializes in the research, production, and sales of steroid raw materials and formulations [1]. - The company's main business revenue composition includes corticosteroids (63.39%), gynecological and family planning medications (20.69%), other products (9.21%), and anesthetics and muscle relaxants (6.71%) [1].

Group 1 - The company has established a market value management system as of April 2025 [2] - The responsibility for market value management lies with the board of directors, with participation from the management team [2] - Further details can be found in the relevant announcements [2]